Compare · MO vs NAGE
MO vs NAGE
Side-by-side comparison of Altria Group Inc. (MO) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MO and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $119.05B, about 443.5x NAGE ($268.4M).
- Over the past year, MO is up 20.8% and NAGE is down 74.8% - MO leads by 95.6 points.
- MO has been more active in the news (17 items in the past 4 weeks vs 2 for NAGE).
- MO has more recent analyst coverage (19 ratings vs 1 for NAGE).
- Company
- Altria Group Inc.
- Niagen Bioscience Inc.
- Price
- $71.29-1.26%
- $3.38-1.89%
- Market cap
- $119.05B
- $268.4M
- 1M return
- +3.23%
- -19.24%
- 1Y return
- +20.77%
- -74.83%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 17
- 2
- Recent ratings
- 19
- 1
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Latest MO
- SEC Form 11-K filed by Altria Group Inc.
- SEC Form 11-K filed by Altria Group Inc.
- Director Kelly Ennis Debra J sold $418,318 worth of shares (5,790 units at $72.25), decreasing direct ownership by 7% to 73,809 units (SEC Form 4)
- Director Strahlman Ellen R sold $145,118 worth of shares (2,000 units at $72.56), decreasing direct ownership by 7% to 25,102 units (SEC Form 4)
- SEC Form SD filed by Altria Group Inc.
- Amendment: SEC Form 10-K/A filed by Altria Group Inc.
- U.S. Smokeless Tobacco Company Announces Plan to Modernize Manufacturing Footprint Through Facility Relocation
- Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Strahlman Ellen R was granted 2,571 shares, increasing direct ownership by 10% to 27,102 units (SEC Form 4)
- Director Stoddart Richard S was granted 2,571 shares, increasing direct ownership by 75% to 6,010 units (SEC Form 4)
Latest NAGE
- Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
- Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
- Niagen Bioscience Announces Participation in Upcoming Investor Conferences
- Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
- SEC Form 10-Q filed by Niagen Bioscience Inc.
- Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
- SEC Form DEFA14A filed by Niagen Bioscience Inc.
- SEC Form DEF 14A filed by Niagen Bioscience Inc.
- Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™